(Q41697696)

English

Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL.

scientific article published on 15 December 2014

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Impact of IKZF1 deletions on long-term outcomes of allo-SCT following imatinib-based chemotherapy in adult Philadelphia chromosome-positive ALL. (English)

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Philadelphia chromosome

1 reference

object named as

Philadelphia chromosome

2 August 2024

based on heuristic

inferred from title

0 references

author name string

M Kim

1

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

J Park

2

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

D-W Kim

3

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Y-J Kim

4

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Y-W Jeon

5

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

J-H Yoon

6

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

S-H Shin

7

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

S-A Yahng

8

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

S-E Lee

9

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

B-S Cho

10

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

K-S Eom

11

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

H-J Kim

12

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

C-Ki Min

13

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

S-G Cho

14

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Y Kim

15

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

J-W Lee

16

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

K Han

17

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

W-S Min

18

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

S Lee

19

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

language of work or name

0 references

publication date

15 December 2014

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Bone Marrow Transplantation

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

50

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

354-362

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

The effect of first-line imatinib interim therapy on the outcome of allogeneic stem cell transplantation in adults with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

High complete remission rate and promising outcome by combination of imatinib and chemotherapy for newly diagnosed BCR-ABL-positive acute lymphoblastic leukemia: a phase II study by the Japan Adult Leukemia Study Group

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Concurrent intensive chemotherapy and imatinib before and after stem cell transplantation in newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia. Final results of the CSTIBES02 trial

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

UKALLXII/ECOG2993: addition of imatinib to a standard treatment regimen enhances long-term outcomes in Philadelphia positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Dasatinib as first-line treatment for adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Detection of MRD may predict the outcome of patients with Philadelphia chromosome-positive ALL treated with tyrosine kinase inhibitors plus chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Impact of minimal residual disease kinetics during imatinib-based treatment on transplantation outcome in Philadelphia chromosome-positive acute lymphoblastic leukemia.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

High-resolution genomic profiling of childhood ALL reveals novel recurrent genetic lesions affecting pathways involved in lymphocyte differentiation and cell cycle progression.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Molecular allelokaryotyping of pediatric acute lymphoblastic leukemias by high-resolution single nucleotide polymorphism oligonucleotide genomic microarray

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Identification and molecular characterization of recurrent genomic deletions on 7p12 in the IKZF1 gene in a large cohort of BCR-ABL1-positive acute lymphoblastic leukemia patients: on behalf of Gruppo Italiano Malattie Ematologiche dell'Adulto Acute

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome-wide classification study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKAROS deletions dictate a unique gene expression signature in patients with adult B-cell acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Biclonal and biallelic deletions occur in 20% of B-ALL cases with IKZF1 mutations.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: a multicenter analysis in Taiwan

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Outcome modeling with CRLF2, IKZF1, JAK, and minimal residual disease in pediatric acute lymphoblastic leukemia: a Children's Oncology Group study

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 deletion is an independent predictor of outcome in pediatric acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Independent prognostic value of BCR-ABL1-like signature and IKZF1 deletion, but not high CRLF2 expression, in children with B-cell precursor ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Reduced-intensity conditioning allogeneic stem cell transplantation is a potential therapeutic approach for adults with high-risk acute lymphoblastic leukemia in remission: results of a prospective phase 2 study.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Comparable long-term outcomes after reduced-intensity conditioning versus myeloablative conditioning allogeneic stem cell transplantation for adult high-risk acute lymphoblastic leukemia in complete remission.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 status as a prognostic feature in BCR-ABL1-positive childhood ALL.

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: a GIMEMA AL WP report

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

IGH@ translocations, CRLF2 deregulation, and microdeletions in adolescents and adults with acute lymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Identification of different Ikaros cDNA transcripts in Philadelphia-positive adult acute lymphoblastic leukemia by a high-throughput capillary electrophoresis sizing method

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ALL)

1 reference

https://api.crossref.org/works/10.1038%2FBMT.2014.281

21 January 2018

Donor-specific differences in long-term outcomes of myeloablative transplantation in adults with Philadelphia-negative acute lymphoblastic leukemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/25501350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Long-Term Follow-Up of the Imatinib GRAAPH-2003 Study in Newly Diagnosed Patients with De Novo Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A GRAALL Study

1 reference

https://pubmed.ncbi.nlm.nih.gov/25501350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Prospective monitoring of BCR-ABL1 transcript levels in patients with Philadelphia chromosome-positive acute lymphoblastic leukaemia undergoing imatinib-combined chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/25501350

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1038/BMT.2014.281

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Dimensions Publication ID

0 references

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

7 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41697696&oldid=2218907533"